Sign Out
BENLYSTA is indicated for reducing disease activity in adult patients with active autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy; treatment of active lupus nephritis in adult patients in combination with background immunosuppressive therapies (see Dosage & Administration).
Benlysta has not been studied and is therefore not recommended in patients with severe active central nervous system lupus.
